56
60
Growth Score
-19 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
468561
Replicor has focused its efforts on developing a cure for HBV and HDV.
- Andrew Vaillant: Chief Scientific Officer
About the Company
Replicor is a clinical-stage company developing novel NUCLEIC ACID-BASED POLYMERS (NAPs): oligonucleotides whose antiviral activity is strictly dependent on the polymer chemistry of oligonucleotides which can be preserved independently of the sequence of nucleotides present. NAPs have a very important safety advantage over all other existing
oligonucleotide-based drugs such as aptamers, antisense oligonucleotides and siRNA: because NAP’s activity is not sequence dependent, NAPs can be engineered with sequences which retain antiviral activity but which do not have pro-inflammatory activity or off target effects common with other oligonucleotide-based drugs, rendering them safe and well tolerated.
